|
|
|
|
This study,
although conducted in Israel, will be
submitted to FDA under MAPS’ Investigational
New Drug (IND) application
for MDMA in the treatment of PTSD
and therefore fits into MAPS’ mission
of developing MDMA as a prescription
medicine approved by both the FDA
and the European Medicines Agency.
|
|
|
|
MAPS-Sponsored MDMA/PTSD Research in Israel:
An Update
Valerie Mojeiko
The MAPS clinical research monitoring team, consisting
of me and MAPS Clinical Program Manager Amy
Emerson, along with MAPS President Rick Doblin, met
with researchers at Beer Yaakov Mental Health Center on
March 7, 2006 and again on March 12. We conducted an
initial prestudy site visit to prepare for the MAPS-sponsored
MDMA study that will take place in Israel with
survivors of war- and terrorism-related PTSD. Moshe
Kotler, M.D., Chair of the Department of Psychiatry at the
Sackler School of Medicine at Tel Aviv University and
former chief psychiatrist of the Israeli Defense Forces, will
be the principal investigator for this study. Rael Strous,
M.D., and Rakefet Rodrigez, M.D., will act as co-therapists.
This study was approved by the ethics committee at
Beer Yaakov Mental Health Center and has also been
approved by the Israel Ministry of Health. Later this
spring, Dr. Strous and Dr. Rodrigez will observe an
experimental session conducted by the Mithoefer’s at the
site of the MAPS-sponsored MDMA/PTSD study in
Charleston, SC, and will participate in an accompanying
training session on the specifics of conducting MAPS’
MDMA-assisted psychotherapy research. This is a necessary
step of preparing the therapists to conduct this type
of therapy, and a useful practice as MAPS begins to
develop a formal training program for psychedelic therapists.
Once this training session has been completed and
after MAPS clinical research monitoring team has
launched the MDMA/PTSD study in Switzerland, we will
begin the logistical preparations for this study. We aim to
begin treating patients in Israel later this year.
We are now working to submit supplementary
documents to the Israel Ministry of Health and to the US
Food and Drug Administration (FDA). This study,
although conducted in Israel, will be
submitted to FDA under MAPS’ Investigational
New Drug (IND) application
for MDMA in the treatment of PTSD
and therefore fits into MAPS’ mission
of developing MDMA as a prescription
medicine approved by both the FDA
and the European Medicines Agency.
There are three phases in investigating a drug as a
prescription medicine. Phase I involves collecting safety
data in animals and humans. Phase II involves several
pilot studies administering the drug to human subjects to
treat a common indication under slightly different
treatment protocols. The current MAPS study in Charleston,
SC, the approved studies in Switzerland and Israel,
and a proposed study in Spain fall under Phase II. When
these Phase II studies are completed, MAPS will submit
the data to the FDA and the regulatory agencies in the
other countries. We will then apply to begin Phase III,
where we will expand to multi-site studies under a shared
protocol to test MDMA therapy in the treatment of PTSD
on a large sample of subjects. These Phase III multi-site
studies, one protocol conducted throughout multiple sites
in the US and one protocol conducted throughout multiple
sites in Europe and Israel, will each involve about
280 total subjects, cost in the range of $2.5 million, and
take two to three years.
The Israeli study differs from MAPS’ original MDMA/
PTSD study conducted by Dr. Michael Mithoefer in the US
in that it has supplemental dosing halfway through each
of the sessions. The Israel study also uses an active placebo
of low dose MDMA, rather than an inactive placebo. This
will make it more difficult for the therapist and subject to
be able to tell whether the subject received an active dose
of MDMA or not, increasing the success of the doubleblind.
In this study we will also collect long-term followup
data for one year after the second experimental session.
The study in Israel also tests the efficacy of using slightly
less staff time, since only one therapist is present during
some of the non-drug therapy sessions, rather than both
therapists. Both therapists are present during all of the
experimental sessions where MDMA is administered, and
at some of the non-drug therapy sessions.
MAPS Clinical Program Manager Amy Emerson has
been of tremendous help in volunteering her time to
implement the rigorous standards required by the US FDA
and the European Medicines Agency in conducting these
clinical trials with MDMA. MAPS Patron Donor Ami
Shinitzky has also been very generous in donating
$10,000 to this study and raising an additional $25,000
of the total of $100,000 needed to conduct this research.
We are now seeking an additional $65,000 for this study.
Please contact the MAPS office if you are interested in
making a donation.• |